8-K current report · filed Jul 30, 2026

PTC THERAPEUTICS, INC. (PTCT) 8-K Current Report: July 30, 2026

Item 7.01Item EX-99.1Item 2.02Item 5.02PTCT overview

Short answer

PTC THERAPEUTICS, INC. (PTCT) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers). Q2 2026 financial results announced for quarter ended June 30, 2026.

PTC THERAPEUTICS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results announced for quarter ended June 30, 2026
  • Full results and management commentary available in Exhibit 99.1 press release
  • Investor focus: quarterly performance, pipeline progress and cash outlook disclosed in the exhibit

Item 5.02 · Departure/Election of Directors or Officers

  • Hege Sollie-Zetlmayer appointed Class III director through 2028, filling a Board vacancy
  • Former PTC chief human resources officer, bringing 30 years of biopharmaceutical and medical device experience
  • Annual director retainer: $50,000, plus reimbursed Board and committee expenses
  • Initial equity grant: 3,475 stock options and 4,000 restricted stock units
  • Pro-rated 2026 equity grant: 1,738 stock options and 2,000 restricted stock units

Item 7.01 · Regulation FD Disclosure

  • Conference call scheduled for July 30, 2026 at 4:30 p.m. Eastern
  • Management to review quarter ended June 30, 2026 financial results
  • Call also covers corporate highlights and updates
  • Access instructions available in Exhibit 99.1

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $360.5M, net income $83.5M versus $64.8M loss, marking a major profitability improvement
  • Product revenue $238.8M, up over 100% year over year, led by Sephience revenue $151.3M, up 21% sequentially
  • 2026 guidance raised to $1.18B–$1.28B total revenue and $850M–$950M product revenue
  • Cash and marketable securities $2.23B, strengthened by $550M 0% convertible notes due 2031
  • Pipeline catalysts include votoplam’s 770-patient Phase 3 study, vatiquinone’s approximately 120-patient study, and PTC303’s planned 2027 clinical entry

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other PTC THERAPEUTICS, INC. 8-K filings

Get the next PTCT 8-K as it lands

Follow PTCT for push alerts, or ask the research agent what this filing means.